Good PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually”. (PPS anybody’s guess ?)
